OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Gainor on the Potential Value of Targeting TROP-2 and CEACAM5 in Lung Cancer

July 23rd 2021

Justin Gainor, MD, discusses the potential value of targeting TROP-2 and CEACAM5 in lung cancer.

Dr. Gandara on Developments in HER2-Targeted Therapies in NSCLC

July 23rd 2021

David R. Gandara, MD, discusses recent developments in HER2-targeted therapies as a treatment for patients with non-small cell lung cancer.

Dr. Rampal on Selecting Among Available JAK Inhibitors in Myelofibrosis

July 22nd 2021

Raajit K. Rampal, MD, PhD, discusses considerations for selecting among the JAK inhibitors ruxolitinib and fedratinib in the treatment of patients with myelofibrosis.

Dr. Carey on the ​Results of the monarchE Trial in HR+/HER2- Breast Cancer

July 22nd 2021

Lisa A. Carey, MD, FASCO, discusses the phase 3 monarchE trial in hormone receptor–positive, HER2-negative breast cancer.

Dr. Burnham on Closing the Gap in Health Disparities in Prostate Cancer

July 22nd 2021

Leanne Burnham, PhD, discusses the need to close the gap in health disparities in prostate cancer.

Dr. Thompson on Emerging Treatment Strategies With BTK Inhibitors in CLL

July 22nd 2021

Meghan Thompson, MD, discusses emerging treatment strategies with BTK inhibitors in chronic lymphocytic leukemia.

Dr. Basho on the Integration of Trastuzumab Deruxtecan in HER2+ Breast Cancer

July 22nd 2021

Reva K. Basho, MD, discusses the integration of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Dr. Pecot on the Growth of Actionable Targets in Lung Cancer

July 22nd 2021

Chad V. Pecot, MD, discusses the growth of actionable targets in lung cancer.

Dr. Sallman on the Efficacy of Pevonedistat Plus Azacitidine in Higher-Risk MDS

July 21st 2021

David Sallman, MD, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome.

Dr. Pollyea on Emerging Therapies in Higher-Risk Myelodysplastic Syndrome

July 21st 2021

Daniel Pollyea, MD, MS, discusses emerging therapies in higher-risk myelodysplastic syndrome.

Dr. Jamieson on Symptom Management in Myelofibrosis

July 21st 2021

Catriona Jamieson, MD, PhD, discusses symptom management in patients with myelofibrosis.

Dr. Kiladjian on Improving Transfusion-Independence Rates With Momelotinib in Myelofibrosis

July 21st 2021

Jean-Jacques Kiladjian, MD, PhD, discusses the potential utility of momelotinib in improving transfusion-independence rates in myelofibrosis.

Dr. Venook on the Unmet Need Addressed by The GALAXY Trial Examining ctDNA in CRC

July 20th 2021

Alan P. Venook, MD, discusses the unmet need addressed by the GALAXY trial, part of the CIRCULATE-Japan project, which is examining circulating tumor DNA in patients with resectable colorectal cancer.

Dr. Xavier on Recent Updates in DLBCL

July 20th 2021

Marin F. Xavier, MD, discusses recent updates in diffuse large B-cell lymphoma based on data from the 2021 ASCO Annual Meeting.

Dr. Jones on Targeting HER2 Alterations in CRC

July 20th 2021

Jeremy C. Jones, MD, discusses targeting HER2 alterations in colorectal cancer.

Dr. Costa Discusses Ongoing Research Efforts in TNBC

July 20th 2021

Ricardo Costa, MD, MSc, discusses ongoing research efforts in triple-negative breast cancer.

Dr. Motzer on the Importance of Assessing Health-Related QOL in RCC

July 20th 2021

Robert J. Motzer, MD, discusses the importance of assessing health-related quality of life in renal cell carcinoma.

Dr. Ahmed on Optimizing Treatment With Axi-Cel in LBCL

July 20th 2021

Sairah Ahmed, MD, discusses optimizing treatment with axicabtagene ciloleucel in large B-cell lymphoma.

Dr. Ghia on Key Findings From the CAPTIVATE Trial in CLL

July 19th 2021

Paolo Ghia, MD, PhD, discusses key findings from the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Verstovsek on Efficacy of Pelabresib Plus Ruxolitinib in Myelofibrosis

July 19th 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy of the combination of pelabresib plus ruxolitinib in the treatment of patients with myelofibrosis.

NEXT PAGE
PREVIOUS PAGE